Patient presents with clinical features suggestive of spinal muscular atrophy (SMA).  Symptoms include progressive muscle weakness, hypotonia, and atrophy, primarily affecting proximal muscles.  Onset of symptoms was noted at [age of onset; specify infantile, childhood-onset, or adult-onset].  Genetic testing, specifically SMN1 gene copy number analysis, was performed and revealed [results of genetic testing; e.g., homozygous deletion of exon 7 of the SMN1 gene].  Differential diagnoses considered included congenital myopathies, muscular dystrophies, and other neuromuscular disorders.  Based on clinical presentation, genetic testing results, and exclusion of other conditions, a diagnosis of spinal muscular atrophy (SMA) type [specify type if known; e.g., type I, II, III, or IV] is confirmed.  Treatment plan includes discussion of available disease-modifying therapies such as nusinersen (Spinraza), risdiplam (Evrysdi), or onasemnogene abeparvovec (Zolgensma), depending on SMA type and patient eligibility.  Supportive care including respiratory support, nutritional management, physical therapy, and occupational therapy will be implemented to address functional limitations and improve quality of life.  Patient and family were counseled on the prognosis and ongoing management of SMA.  Referral to a multidisciplinary SMA clinic is recommended for comprehensive care.  Follow-up scheduled in [timeframe] to monitor disease progression and response to treatment.  ICD-10 code G12.0 (spinal muscular atrophy) and relevant CPT codes for genetic testing and therapeutic interventions will be documented for medical billing and coding purposes.